Loading...

Home
Stock
AZNCF

AZNCF News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Forecast Technical Valuation Financials Earnings News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
News Release

Market

Market Analysis
Crypto
Market Movers
Stock Monitor
All US Stocks

Strategies

AI Stock Picker
Swing Trading
QuantAI Alpha Pick
CoinSwing
Daytrading Radar
Crypto Radar
Char Pattern Detection

Resource

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat with Tia
AI Screener
Backtesting Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Option Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Monitor News

Compare

TradingView
Seeking Alpha

AZNCF News

Is There More Room for Growth After AstraZeneca's Impressive 30% Surge in 2025?

Dec 04 2025Yahoo Finance

Pfizer CEO Albert Bourla asserts that the company's bold pursuit of Metsera demonstrates its 'right to dominate' the obesity market.

Nov 13 2025Yahoo Finance

Earnings Overview: AstraZeneca Surpasses Q3 Projections and Confirms FY 25 Forecast

Nov 06 2025SeekingAlpha

AstraZeneca surpasses revenue and profit expectations; maintains FY25 forecast

Nov 06 2025SeekingAlpha

Trump Secures AstraZeneca Agreement to Reduce Medicaid Drug Costs — Major Pharmaceutical Companies Confront New Challenges

Oct 15 2025Yahoo Finance

BeOne Medicines, an IBD 50 Stock, Competing with Major Players in Cancer Therapy

Oct 03 2025Yahoo Finance

TAGRISSO® (osimertinib) combined with chemotherapy shows nearly four years of median overall survival, marking the longest benefit recorded in a global Phase III trial for advanced lung cancer with EGFR mutations.

Sep 07 2025Yahoo Finance

AstraZeneca's $80 Billion Goal Receives Major Boost from New Hypertension Findings

Aug 30 2025Yahoo Finance

AZNCF Events

an image of No data

No data

AZNCF Monitor News

an image of No data

No data

AZNCF Earnings Analysis

an image of No Data

No Data

People Also Watch